Woodmansee D P, Simon R A
Division of Allergy and Immunology, Scripps Clinic, La Jolla, California 92037, USA.
Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 1):548-52. doi: 10.1016/S1081-1206(10)62868-2.
Atopic dermatitis is a common chronic inflammatory skin condition. Current therapies are often insufficient to control the degree of inflammation and pruritus seen in this disease.
To examine the efficacy of zileuton in treating atopic dermatitis by measuring both subjective and objective outcome parameters.
This was an open-label pilot study using zileuton to treat atopic dermatitis. Following a 1-week run-in period off all corticosteroids and antihistamines, six adult patients received 6 weeks of zileuton 600 mg po QID. Subjects were not allowed to use their usual atopic dermatitis medications during the study. At baseline, and at 2, 4, and 6 weeks into the zileuton course, patients were asked to report on their disease dissatisfaction and their pruritus. Objective skin scoring was also performed by an examiner at these visits.
Disease dissatisfaction score decreased from a mean of 8 (out of a possible 10) to 4.4 over the 6-week period (P = .03). Pruritus scores showed a trend toward improvement during the study, decreasing from a mean of 7.3 to 4.3 (out of a possible 10, P = .06). Objective skin erythema scores decreased from a baseline mean of 24 (out of a possible 60) to 14 following zileuton treatment (P = .03).
In this pilot study, zileuton showed efficacy in significantly improving the symptoms and objective skin findings seen in atopic dermatitis. The encouraging results seen in this trial should encourage larger, placebo-controlled studies looking at this novel approach toward treating this condition.
特应性皮炎是一种常见的慢性炎症性皮肤病。目前的治疗方法往往不足以控制该疾病中出现的炎症程度和瘙痒症状。
通过测量主观和客观结果参数来检验齐留通治疗特应性皮炎的疗效。
这是一项使用齐留通治疗特应性皮炎的开放标签试点研究。在停用所有皮质类固醇和抗组胺药1周的导入期后，6名成年患者接受了为期6周的齐留通治疗，口服剂量为600毫克，每日4次。研究期间，受试者不得使用其常用的特应性皮炎药物。在基线时以及齐留通疗程的第2、4和6周，要求患者报告其对疾病的不满程度和瘙痒情况。在这些访视时，检查人员也进行了客观的皮肤评分。
在6周期间，疾病不满评分从平均8分（满分10分）降至4.4分（P = .03）。瘙痒评分在研究期间呈改善趋势，从平均7.3分降至4.3分（满分10分，P = .06）。齐留通治疗后，客观皮肤红斑评分从基线平均24分（满分60分）降至14分（P = .03）。
在这项试点研究中，齐留通在显著改善特应性皮炎的症状和客观皮肤表现方面显示出疗效。该试验中看到的令人鼓舞的结果应促使开展更大规模的、安慰剂对照研究，以探讨这种治疗该疾病的新方法。
